ArticleJournal of translational medicine2025
CDH3 promotes the progression of lung adenocarcinoma through driving epithelial-mesenchymal transition progress.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-Omics Integration Identifies a CDH3-Associated Malignant Epithelial State and Immunosuppressive Niche to Predict Prognosis in Thymic Epithelial Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A pyroptosis-related molecular signature stratifies prognosis and highlights GSDMB-mediated malignancy in intrahepatic cholangiocarcinoma.Biology direct · 2026Article
- Single-cell mitophagy signature-based artificial intelligence model enhances prediction of prognosis and immunotherapy response in non-small-cell lung cancer.Respiratory research · 2026Article
- CDH3 in human tumors: tumor biology and potential therapeutic target.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCadherin-3 (CDH3) participates in multiple oncogenic processes, but its biological role and mechanisms in lung adenocarcinoma (LUAD) remain inadequately understood.
methodsWe analyzed CDH3 expression in LUAD versus adjacent normal tissues and assessed its association with patient outcomes. Bioinformatics, immune scoring, and single-cell analysis were used to explore CDH3's links to epithelial-mesenchymal transition (EMT), inflammatory responses, TNF pathway activation, glycolysis, hypoxia, and tumor-associated macrophage infiltration. Independent immunotherapy datasets (IMvigor210, GSE91061) were evaluated for CDH3's relationship to treatment response. In vitro CDH3 knockdown studies assessed effects on glycolysis, EMT, proliferation, and migration in LUAD cells, and in vivo tumor growth was measured post-knockdown.
resultsCDH3 expression was significantly elevated in LUAD tissues and correlated with poorer patient survival. High CDH3 expression associated with EMT, inflammatory responses (including TNF pathway), glycolysis, and hypoxia. It also promoted tumor-associated macrophage infiltration and impaired anti-tumor immunity. Patients with low CDH3 expression showed improved immunotherapy response and prognosis. CDH3 knockdown suppressed LUAD cells glycolysis process, EMT, proliferation, and migration in vitro, and significantly repressed tumor growth in vivo.
conclusionsCDH3 drives LUAD progression by promoting EMT, tumor growth, metastasis, and immunosuppression. It represents a promising diagnostic/prognostic biomarker and a novel therapeutic target for LUAD immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.